Lilly Raises Profit Forecast on Amylin's $1.26B Payment

Source: Reuters, Toni Clarke and Esha Dey (8/9/12)

"Lilly plans to use the cash to advance its 'pipeline of more than 60 potential new medicines,' among other corporate uses."

Reuters, Toni Clarke and Esha Dey

Eli Lilly and Co (LLY.N) raised its 2012 net profit forecast for the second time in as many weeks to reflect an early payment of $1.26 billion from former partner Amylin Pharmaceuticals Inc, which has been acquired by Bristol-Myers Squibb Co (BMY.N).

Diabetes specialist Amylin had ended its decade-long partnership with Lilly in November. The companies were partners in marketing Amylin's diabetes drug Byetta and its longer-acting version, Bydureon. Bristol, which completed its Amylin purchase on Wednesday, has paid $1.7 billion apart from the cash consideration to cover Amylin's debt and its obligations to Eli Lilly.

Lilly plans to use the cash to advance its "pipeline of more than 60 potential new medicines," among other corporate uses. . .View Full Article

A Health Sciences Stock Positioned To Break Out of a Giant Base Pattern
Source: Clive Maund (05/27/2025)

Technical Analyst Clive Maund explains why he thinks PreveCeutical Medical Inc. (PREV:CSE; PRVCF:OTCMKTS) is ready to break out and is rated a Strong Buy.

Co. Poised to Begin Major New Bull Market
Source: Clive Maund (05/23/2025)

Technical Analyst Clive Maund explains why he thinks Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) is an Immediate Strong Buy.

Co. Prepares to Roll Out Wound Irrigating Solution
Source: Richard Ryan (05/21/2025)

BioLargo Inc.'s (BLGO:OTCQX) subsidiary has all the necessary partners in place and working on integrating the various systems, such as purchasing, accounting, forecasting, logistics and quality assurance, noted an Oak Ridge Financial report.

Interim Data From TID Trial Are Positive
Source: Streetwise Reports (05/15/2025)

Sernova Biotherapeutics Inc.'s (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) regenerative treatment delivered via its Cell Pouch Bio-hybrid Organ is proving to result in insulin independence, among other outcomes. Read what one analyst says are the implications of this clear medical benefit.

Biotech Firm Unlocks Alzheimer's Market with U.S. Clinic Launch
Source: Streetwise Reports (05/13/2025)

Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) has acquired NoBrainer Imaging, unlocking Alzheimer's PET scan clinics in Florida, Los Angeles, five select U.S. cities, and Canada. Read more to explore the growth potential.